Dexamethasone dose and length of hospital stay among hospitalized COVID-19 patients: a retrospective cross-sectional study in Malaysia
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20233429Keywords:
COVID-19, Dexamethasone, Outcomes, MalaysiaAbstract
Background: Dexamethasone is a potent corticosteroid that has been widely used as COVID-19 treatment. However, optimal dose of dexamethasone in COVID-19 treatment and how its different doses affect the patient outcomes is uncertain. This retrospective study aimed to evaluate the use of dexamethasone dose and length of hospital stay in COVID-19 patients admitted to two public hospitals in the east coast region of Malaysia between February 2020 and August 2021.
Methods: This study included all hospitalized patients who were receiving dexamethasone during the study period. Dexamethasone doses were categorized into high dose (≥15 mg/day), moderate dose (7-14 mg/day) and low dose (≤6 mg/day). A multivariable logistic regression was conducted to evaluate the potential risk factors associated with length of hospital stays.
Results: Of 119 patients enrolled, majority (40%) of patients received high dose dexamethasone, followed by 33% received moderate dose and 27% received low dose. Patients who received high doses were associated with extended hospital stays of 4-5 days and more frequently required mechanical ventilation. Multivariable logistic regression showed that elderly (OR=1.03; 95% CI=1.00-1.06, p=0.001) and severe stage of COVID-19 (stage 4-stage 5) upon hospital admission (OR=2.79; 95% CI=1.17-6.68, p=0.021) increased the risk of prolonged hospital stay.
Conclusions: COVID-19 patients treated with high and moderate doses of dexamethasone were associated with longer hospital stay and required mechanical ventilation compared to those on low doses. Future studies are needed to provide more evidence on benefits of low dexamethasone dose in COVID-19 patients.
References
Organisation for Economic Co-operation and Development. The territorial impact of COVID-19: managing the crisis across levels of government, 2020. Available from: https://www.oecd.org/coronavirus/policy-responses/the-territorial-impact-of-covid-19-managing-the-crisis-across-levels-of-government-d3e314e1/. Accessed on 19 March 2023.
Venkatasubbaiah M, Reddy PD, Satyanarayana SV. Literature-based review of the drugs used for the treatment of COVID-19. Curr Med Res Pract. 2020;10(3):100-9.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin Infect Dis. 2023;76(8):1403-11.
Butler CC, Hobbs FR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281-93.
World Health Organization. Clinical Management of COVID-19. 2023. Available from: https://www.who.int/teams/health-care-readiness/covid-19. Accessed on 19 March 2023.
National Institutes of Health. Corticosteroids. 2022. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/#:~:text=If%20dexamethasone%20is%20not%20available,Prednisone%2040%20mg. Accessed on 19 March 2023.
Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (Recovery): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52.
Dastenae ZH, Bahadori A, Dehghani M, Asadi-Samani M, Izadi I, Shahraki HR. Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect Dis. 2022;122:659-64.
Munch MW, Myatra SN, Vijayaraghavan BKT. Effect of 12mg vs 6mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID steroid 2 randomized trial. J Am Med Assoc. 2021;326(18):1807-17.
Ministry of Health Malaysia. Clinical management of confirmed COVID-19 case in adult and pediatric. 2022. Available from: https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX-2E-CLINICAL-MANAGEMENT-OF-CONFIRMED-COVID-19-31052022.pdf. Accessed on 17 March 2023.
Maskin LP, Olarte GL, Palizas F, Velo AE, Lurbet MF, Bonelli I, et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:1-3..
Liu Z, Li X, Fan G, Zhou F, Wang Y, Huang L, et al. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect. 2021;27(1):112-7.
Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother psychosomat. 2022;91(1):8-35.
Sim BL, Chidambaram SK, Wong XC, Pathmanathan MD, Peariasamy KM, Hor CP, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study. Lancet Reg Health West Pac. 2020;4.
Tustumi F. Choosing the most appropriate cut-point for continuous variables. Rev Col Brasil Cirurg. 2022;49:e20223346.
Josephat, PK, Ame A. Effect of testing logistic regression assumptions on the improvement of the propensity scores. Int J Stat Appl. 2018;8(17):9-17.
Marcoulides KM, Raykov T. Evaluation of variance inflation factors in regression models using latent variable modelling methods. Educ Psychol Measure. 2019;79(5):874-82.
Zamarrón E, Carpio C, Villamañán E, Álvarez-Sala R, Borobia AM, Gómez-Carrera L, et al. Impact of systemic corticosteroids on hospital length of stay among patients with COVID-19. Farm Hosp. 2023;47(2):55.
Birhanu A, Merga BT, Ayana GM, Alemu A, Negash B, Dessie Y. Factors associated with prolonged length of hospital stay among COVID-19 cases admitted to the largest treatment center in Eastern Ethiopia. SAGE Open Med. 2022;10:20503121211070366.
Abdelzaher H, Saleh BM, Ismail HA, Hafiz M, Gabal MA, Mahmoud M, et al. COVID-19 genetic and environmental risk factors: a look at the evidence. Front Pharmacol. 2020;11:579415.
Taboada M, Rodríguez N, Varela PM, Rodríguez MT, Abelleira R, González A, et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J. 2022;60(2).
Damayanthi H, Prabani K, Weerasekara I. Factors associated for mortality of older people with COVID-19: a systematic review and meta-analysis. Gerontol Geriatr Med. 2021;7:23337214211057392.
Sanyaolu A, Okorie C, Marinkovic A. Comorbidity and its impact on patients with COVID-19. Springerlink Comprehens Clin Med. 2020;2:1069-76.
SeyedAlinaghi S, Afsahi AM, MohsseniPour M, Behnezhad F, Salehi MA, Barzegary A, et al. Late complications of COVID-19: a systematic review of current evidence. Arch Acad Emerg Med. 2021;9(1).
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. J Am Med Assoc. 2020;324(13):1-11.
